Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice

Canadian Journal of Cardiology

Volumn 24, Issue 10, 2008, Pages 771-775

  Ahmad, Mayraj ^a   Schwalm, Jon David R ^a   Velianou, James L ^a   Pericak, Dan ^a   Natarajan, Madhu K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Coronary artery disease; Drug eluting stents; Paclitaxel; Percutaneous coronary intervention; Restenosis; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; BIOMATERIAL; METAL; TUBULIN MODULATOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; RESTENOSIS; RETROSPECTIVE STUDY; THROMBOSIS; ANGIOCARDIOGRAPHY; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; FOLLOW UP; INSTRUMENTATION; MIDDLE AGED; PROSTHESIS; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY THROMBOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METALS; MIDDLE AGED; PACLITAXEL; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 54449099746     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70682-2     Document Type: Article

References (17)

1. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
2. Colombo A, Drzewiecki J, Banning A, et al; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. Circulation 2003;108:788-94.
3. Stone GW, Ellis SG, Cox DA, et al. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
4. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting stent: The TAXUS-IV trial. Circulation 2004;109:1942-7.
5. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
6. Bavry AA, Kumbhani DJ, Helton T, et al. What is the risk of stent thrombosis associated with the use of paclitaxel eluting stents for percutaneous coronary intervention? J Am Coll Cardiol 2005;45:941-6.
7. Moreno R, Fernandez C, Hernandez R, et al. Drug eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
8. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
9. Ong TL, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41.
10. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; Principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J 2001;22:554-72.
11. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190.
12. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358.
13. Urban P, Gershlick AH, Guagliumi G, et al. One-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41.
14. Kereiakes DN, Choo JK, Young JJ, et al. Thrombosis and drug-eluting stents: A critical appraisal. Rev Cardiovasc Med 2004;5:9-15.
15. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
16. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real world': The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
17. Schwalm JD, Ahmad M, Velianou JL, Natarajan MK. Primary and rescue percutaneous coronary intervention with paclitaxel-eluting stent implantation in ST-elevation myocardial infarction. Am J Cardiol 2006;97:1308-10.